Skip to main content

Market Overview

UPDATE: Wedbush Initiates Coverage on Fate Therapeutics on Potential of Modified HSCs


In a report published Monday, Wedbush analyst David M. Nierengarten initiated coverage on Fate Therapeutics (NASDAQ: FATE) with an Outperform rating and $14.00 price target.

In the report, Wedbush noted, “FATE is developing modified hematopoietic stem cells (HSCs) to improve outcomes in allogeneic transplants. These modified HSCs could improve outcomes in hematological cancers and lysosomal storage diseases (LSDs), where stem cell transplants are the only potentially curative therapy. FATE's lead product candidate, ProHema, is comprised of ex vivo optimized HSCs derived from umbilical cord blood. A Phase Ib study of ProHema in patients undergoing stem cell transplants showed an improvement of 3 days in median engraftment time, relative to historical controls, and patients also experienced better outcomes in various secondary measures.”

Fate Therapeutics closed on Friday at $6.93.

Latest Ratings for FATE

Mar 2021SVB LeerinkMaintainsOutperform
Mar 2021Wells FargoMaintainsOverweight
Feb 2021WedbushDowngradesOutperformNeutral

View More Analyst Ratings for FATE
View the Latest Analyst Ratings


Related Articles (FATE)

View Comments and Join the Discussion!

Posted-In: David M. Nierengarten WedbushAnalyst Color Initiation Analyst Ratings

Latest Ratings

PHXSeaport GlobalInitiates Coverage On
AFCGLake StreetInitiates Coverage On29.0
OSSNoble Capital MarketsUpgrades7.0
NCNOGabelli & Co.Upgrades
HAECJS SecuritiesUpgrades
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at